Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 246

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Vimentin is a novel AKT1 target mediating motility and invasion

Open access
Zhu, Q-S, Rosenblatt, K, Huang, K-L, Lahat, G, Brobey, R, Bolshakov, S, Nguyen, T, Ding, Z, Belousov, R, Bill, K, Luo, X, Lazar, A, Dicker, A, Mills, G B, Hung, M-C, Lev, D·2011·Oncogene

Abstract

The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors of AKT are involved in survival, growth and metabolic-related pathways. In contrast, contradictory data relating to AKT effects on cell motility and invasion, crucial prometastatic processes, have been reported pointing to a potential cell type and isoform type-specific AKT-driven function. By implication, study of AKT signaling should optimally be conducted in an appropriate intracellular environment. Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies of mesenchymal origin, is poor, reflecting our modest ability to control metastasis, an effort hampered by lack of insight into molecular mechanisms driving STS progression and dissemination. We examined the impact of the cancer progression-relevant AKT pathway on the mesenchymal tumor cell internal milieu. We demonstrate that AKT1 activation induces STS cell motility and invasiveness at least partially through a novel interaction with the intermediate filament vimentin (Vim). The binding of AKT (tail region) to Vim (head region) results in Vim Ser39 phosphorylation enhancing the ability of Vim to induce motility and invasion while protecting Vim from caspase-induced proteolysis. Moreover, vimentin phosphorylation was shown to enhance tumor and metastasis growth in vivo. Insights into this mesenchymal-related molecular mechanism may facilitate the development of critically lacking therapeutic options for these devastating malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2010.421

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 246

Metadata

Authors
Zhu, Q.-S., Rosenblatt, K., Huang, K.-L., Lahat, G., Brobey, R., Bolshakov, S., Nguyen, T., Ding, Z., Belousov, R., Bill, K., Luo, X., Lazar, A., Dicker, A., Mills, G. B., Hung, M.-C., & Lev, D.
Venue
Oncogene
Published
2010-09-20
Volume
30
Issue
4
Pages
457-470
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2014331589
Cited by
246
References
1
FWCI
3.43
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vimentin is a novel AKT1 target mediating motility and invasion. https://app.cochat.ai/papers/10.1038/onc.2010.421
The paper
Zhu, Q.-S., Rosenblatt, K., Huang, K.-L., Lahat, G., Brobey, R., Bolshakov, S., Nguyen, T., Ding, Z., Belousov, R., Bill, K., Luo, X., Lazar, A., Dicker, A., Mills, G. B., Hung, M.-C., & Lev, D. (2011). Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. https://doi.org/10.1038/onc.2010.421

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.